Protagonist Presents Updated Long-Term Findings From Rusfertide Phase 2 REVIVE Study At EHA2024, Demonstrating Sustained Hematocrit Control
Portfolio Pulse from Benzinga Newsdesk
Protagonist Therapeutics presented updated long-term findings from its Phase 2 REVIVE study of Rusfertide at EHA2024, showing sustained hematocrit control.
June 14, 2024 | 8:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protagonist Therapeutics presented updated long-term findings from its Phase 2 REVIVE study of Rusfertide at EHA2024, showing sustained hematocrit control.
The positive long-term findings from the Phase 2 REVIVE study of Rusfertide are likely to boost investor confidence in Protagonist Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100